In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Adams Street and Latterell lead Naurex’s $18mm Series A financing

Executive Summary

Adams Street Partners and Latterell Venture Partners co-led neurology therapeutics developer Naurex Inc.’s $18mm Series A financing, which also included investments by Druid BioVentures, Genesys Capital, PathoCapital, H. Lundbeck AS, Takeda Ventures, and Shire PLC. A member of PathoCapital has become the company’s chairman, and executives from Adams and Latterell joined the board.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies